REGENERON PHARMACEUTICALS
REGNNASDAQTrading Snapshot
- Day Range
- $784.54 – $809.77
- 52-Week Range
- $541.00 – $821.11
- Volume
- $4.24B
- Avg Volume
- $3.81B
- Shares Outstanding
- 104.8M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $15.80B
- Last Q Revenue
- $4.36B
- P/E Ratio
- 18.9
- P/S Ratio
- 5.3x
- EPS (TTM)
- $40.45
- Dividend Yield
- 0.46%
Why Investors Own REGN
- ✓High-growth profile — revenue up +59.4% YoY with expanding Biotech exposure.
- ✓Healthy economics — 56% gross margin and 24% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About REGENERON PHARMACEUTICALS
A company profile for REGENERON PHARMACEUTICALS isn’t available yet — check back soon.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
American Century Focused Dynamic Growth Fund Q2 2026 Portfolio Review
U.S. equities posted double-digit quarterly gains despite volatility stemming from the Iran conflict. Read more here.
Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight
Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals’ recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests momentum has...
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update
Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing. Phase 1/2 chemotherapy combination study focused in 2L mCRC initiating in Q4 2026 - - Phase 1 monotherapy expansion cohorts initiating in Q3 2026 in gastric and gastroesophageal junction (GEJ), EpCAM-selected pancreatic ductal adenocarc
Intellia Therapeutics Inc (NTLA) (Q2 2026) Earnings Call Highlights: Advancing LONVOSI Toward ...
Intellia reports positive Phase III data for LONVOSI, resumes NEXI trials with new HLA safety insights, and maintains cash runway into 2028.